DailyIQ
Last updated1 minute ago

GILD·Gilead Sciences, Inc.

$144.27
-0.36 (-0.25%)
Overnight$144.23-0.04 (-0.03%)
High
$146.14
Open
$145.11
Market Cap
178.38B
52W High
$157.29
Low
$142.59
P. Close
$144.27
P/E
20.96
52W Low
$112.06
Fwd P/E
14.58
DailyIQ Est.
$164.33
Inst. Ownership
49.2%
Short Interest
1.48%
Days to Cover
3.6
Technical Score (1D)
45
NEUTRAL
News Sentiment
65
BULLISH
On Oct 6, Gilead Sciences announced a five‑year extension with Cognizant Technology Solutions to enhance its DevOps capabilities and deploy agentic AI tools across selected technology programs. The agreement was intended to streamline processes, accelerate delivery, and increase efficiency for Gilead’s priority projects. The deal reflected a strategic partnership that supports Gilead’s ongoing digital transformation efforts. The announcement highlighted the focus on simplifying processes and improving delivery within the company’s technology programs. No additional developments were reported for the company on that date.
LOW TARGET
$123 -14.7%
1 analysts
MEAN TARGET
$159 +10.0%
22 analysts
HIGH TARGET
$180 +24.8%
16 analysts
PRICE RANGE
$123.00 - $180.00
SB / B / H / S / SS
9/21/7/1/1
DAILYIQ EST.
$164.33 (+13.9%)
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NMS
Country
United States
Website
Symbol
GILD
Description
Gilead Sciences is a biopharmaceutical company focused on discovering, developing, and marketing medicines to address significant unmet medical needs globally. The company's core business centers on treatments for viral diseases, including HIV/AIDS and hepatitis, with a portfolio of established therapies such as Biktarvy, Genvoya, and Epclusa. Beyond virology, Gilead offers oncology products like Yescarta and Trodelvy, as well as treatments for pulmonary arterial hypertension and invasive fungal infections. Gilead leverages strategic collaborations with other pharmaceutical and biotechnology companies, including Arcus Biosciences and Merck, to expand its research and development capabilities and pipeline of potential future therapies. Founded in 1987, the company is headquartered in Foster City, California.
Bought (1Y)
0 shares
$0
Sold (1Y)
196,589 shares
$26.9M
O'Day Daniel PatrickChairman & CEO
Sell3,000 shares2026-10-01
O'Day Daniel PatrickChairman & CEO
Sell12,000 shares2026-10-01
Burkhart ErinSVP, Controllership
Option Exercise2,223 shares2026-09-22
Burkhart ErinSVP, Controllership
Tax Withholding768 shares2026-09-22
Burkhart ErinSVP, Controllership
Option Exercise2,223 shares2026-09-22
72/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
78.8%
Net Margin
28.9%
Revenue CAGR
11.4%
Current Ratio
1.55x
Debt / Equity
1.10x
Return on Equity
37.5%
Earnings Summary
Gilead Sciences, a biopharmaceutical company headquartered in Foster City, California, specializes in viral therapies, notably HIV/AIDS and hepatitis, while also developing oncology and pulmonary products, positioning it within the broader healthcare drug manufacturers sector. In the most recent four quarters, Gilead’s earnings per share have trended upward, with Q4 2024 EPS of $1.90 beating the $1.70 estimate, Q1 2025 EPS of $1.81 versus $1.78, Q2 2025 EPS of $2.01 versus $1.96, and Q3 2025 EPS of $2.47 versus $2.14; revenue followed a similar pattern, rising from $7.57 bn in Q4 2024 to $7.77 bn in Q3 2025, a 2.6% YoY increase in the latest quarter. Historically, Gilead has maintained a consistent EPS beat streak, with the company surpassing analyst expectations in each of the last four quarters, while revenue growth has slowed to a modest 2.7% over five years, indicating a plateau in top‑line expansion despite solid profitability. Recent analyst commentary highlights a narrowing profitability profile driven by rising operating costs and stagnant revenue growth, suggesting that investors may reassess the sustainability of Gilead’s cash‑producing status; the lack of new product launches or regulatory approvals further underscores the absence of a near‑term catalyst.

EPS

EstBeatMiss
$-8.86$-5.66$-2.45$0.75$3.95Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.15 - -
Q2'26$-7.38$-6.75+8.5%
Q1'26$1.95$2.03+4.0%
Q4'25$1.98$1.86-6.2%
Q3'25$2.14$2.47+15.7%
Q2'25$1.96$2.01+2.7%

Revenue

EstBeatMiss
$6.8B$7.1B$7.4B$7.8B$8.1BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$7.9B - -
Q2'26$7.5B$7.8B+3.4%
Q1'26$7.1B$7.0B-1.3%
Q4'25$6.9B$7.9B+14.1%
Q3'25 - $7.8B -
Q2'25 - $7.1B -

Market Data

GILD Stock Snapshot

NEUTRAL45/100
$144.23−$0.04 (0.0%)
Market cap
178.38B
P/E ratio
21.0
Day range
$142.59 – $146.14
News sentiment
65/100 · Bullish
Analyst target
$158.65 (+10.0%)
Consensus
Buy · 39 analysts
52-week range+28.7% off low · -8.3% from high
$112.06$157.29
Price $144.23 DailyIQ Est. $164.33

Momentum has flattened on GILD, leaving the next move dependent on news rather than the chart. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.

Reverse DCF

What growth is priced into GILD?

CHEAP

At today's price, Gilead Sciences, Inc. needs to grow free cash flow about 4.1% a year for the next 10 years to justify its valuation at a 7.75% cost of capital. Over its actual history it has compounded free cash flow at 9.8% a year, so the market is asking for 5.8 percentage points below its own delivered rate. On that basis GILD looks priced below what its own growth record supports.

Implied FCF growth
4.1%
Historical FCF CAGR
9.8%
Growth gap
-5.8 pts
Verdict
CHEAP
Discount rate (WACC)
7.75%
Beta
0.61

Behaviour On Record

What GILD's own history says about today's numbers

Realized volatility (21d)
18.9% 26th pct
Below its peak
-7.4%
vs 200-day average
+5.5%
Up days (1y)
48%

Gilead Sciences, Inc. is currently running 18.9% annualised volatility over the last 21 sessions. Measured against GILD's own 13 years of daily returns rather than a market-wide average, that is the 26th percentile — on the quiet side for this stock, against a typical reading of 22.6%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

GILD is trading -7.4% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -21.4%, and the deepest was -36.5% in 2020. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +5.5% from its 200-day moving average. Against every other day in its history, that gap ranks at the 65th percentile — a somewhat wider gap than its own norm. Over the past year GILD closed higher on 48% of sessions, and it is currently 6 sessions into a falling streak.

On October specifically: over 13 years of records, GILD finished the month higher 8 of 13 times, with a median return of +5.3% and an average of +2.6%. Its strongest month historically has been January at +3.3% on average, its weakest December at -2.4%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: GILD has opened more than 2% away from the prior close in 30 of 3,268 sessions (0.9% of the time), with the largest gaps running +3.3% and -5.6%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, GILD moved an average of 3.1% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.7% and a largest of +7.2%.

All figures computed from 3,269 daily closes between 2013-10-07 and 2026-10-06, split-adjusted, recomputed daily. Percentiles are against GILD's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of GILD's sector?

Gilead Sciences, Inc. sits in the Health Care sector, currently ranked 8th of 12 GICS sectors by relative-strength rotation score (lagging).

Sector rank
#8 of 12
Sector state
Lagging
Sector rotation score
0

Options Market

What is the options market pricing for GILD?

CallsPuts

For Gilead Sciences, Inc.'s nearest expiry (2026-10-09, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.62), with at-the-money implied volatility around 35.4%. The options market is pricing roughly a ±2.8% move by that expiry — a range of about $140.21–$148.42.

Put/call ratio (2026-10-09)
0.62
ATM implied volatility
35.4%
Total open interest
5,417
Expected move by 2026-10-09
±2.8% ($140.21–$148.42)

Analyst Rating Changes

Are analysts turning bullish or bearish on GILD?

HSBC most recently reiterated its rating on Gilead Sciences, Inc. to Buy on Sep 10, 2026 with a price target of $175 (from $155). Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.

Latest action
HSBC — Buy
90-day upgrades
0
90-day downgrades
1
Net rating momentum
-1
DateFirmActionRatingPrice target
Sep 10, 2026HSBCMaintainedBuy$155 → $175
Aug 5, 2026RBC CapitalMaintainedSector Perform$120 → $123
Aug 5, 2026Cantor FitzgeraldReiteratedOverweight$155
Aug 5, 2026NeedhamReiteratedBuy$170
Jul 29, 2026BarclaysMaintainedEqual-Weight$155 → $145
Jul 27, 2026Morgan StanleyMaintainedOverweight$166 → $165
Jul 21, 2026Leerink PartnersDowngradeOutperform → Market Perform$146 → $127
Jul 8, 2026Morgan StanleyMaintainedOverweight$168 → $166
Jul 7, 2026RBC CapitalMaintainedSector Perform$122 → $120
Jul 7, 2026Truist SecuritiesMaintainedBuy$157 → $156
Jul 6, 2026Cantor FitzgeraldReiteratedOverweight$155
Jul 6, 2026HSBCUpgradeHold → Buy$133 → $155

GILD Competitive Positioning

Gilead Sciences, Inc. (GILD) is tracked alongside these names in Drug Manufacturers - General on DailyIQ — ranked by market cap, with today's move alongside.

News Sentiment Analysis

Sentiment gathered from recent headlines

65/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Gilead Sciences entered a five‑year extension with Cognizant Technology Solutions to enhance its DevOps capabilities and deploy agentic AI tools across selected technology programs. The agreement aims to streamline processes, accelerate delivery, and increase efficiency for Gilead’s priority projects. The deal was announced on October 6 and reflects a strategic partnership that supports Gilead’s ongoing digital transformation efforts.
What did this article say?
On October 5, Gilead Sciences and Nurix Therapeutics announced a two‑year extension of their oncology research collaboration, marking the second extension of the program. The agreement includes a $10 million extension fee for Nurix and maintains the framework that could yield up to $1.3 billion in future milestone payments. The extension reinforces Gilead’s commitment to the partnership and provides additional financial support for ongoing research. The deal does not alter Gilead’s broader pipeline but strengthens its position in oncology development. The extension is viewed as a positive, albeit incremental, development for Gilead’s oncology strategy.
What did this article say?
On October 5, Gilead Sciences reported a 3.98% dividend yield that met a high‑quality dividend screen. The company’s profitability remains robust while its valuation stays attractive compared to peers. The dividend policy provides steady income for investors and supports the firm’s valuation narrative. No material guidance changes or risk events were disclosed that would alter the outlook.
What did this article say?
On October 5, Nurix Therapeutics and Gilead Sciences announced a second two‑year extension of the research term for an undisclosed oncology program under their joint collaboration. The extension reaffirms Gilead’s commitment to the partnership and its targeted protein degradation platform. The deal preserves co‑development and 50/50 profit‑sharing rights for up to two U.S. programs. The extension is viewed as a positive reinforcement of the collaboration’s potential without indicating immediate commercial milestones.
What did this article say?
Gilead Sciences extended its drug discovery partnership with Nurix Therapeutics, adding $10 million in funding. The agreement continues to support Nurix’s development of targeted protein degradation therapies. The extension signals confidence in Nurix’s pipeline and provides additional resources for preclinical and early clinical work. The deal does not alter Gilead’s overall strategic direction but reinforces its commitment to innovative therapeutic modalities.
What did this article say?
Gilead Sciences closed the day down 1.87% at $144.74, trailing the S&P 500’s 0.73% gain. The company’s shares had fallen 2.46% over the past month, while analysts noted a projected earnings decline of 12.96% for the upcoming quarter and a modest 0.3% revenue increase. Full‑year estimates forecast a negative earnings per share of $0.48 and a 4.4% revenue rise.
What did this article say?
Legend Biotech’s multiple myeloma therapy Carvykti faces significant competitive pressure from Gilead Sciences’ anticel and Johnson & Johnson’s Tec‑Dara as the FDA decision approaches. UBS analysts noted that Carvykti’s limited expansion into second‑ and third‑line patients leaves it vulnerable to anticel’s potential fourth‑line‑plus approval. The report warned that bispecific antibodies could erode Carvykti’s position in earlier treatment lines, potentially weighing on Legend’s stock until new data or program updates emerge.
What did this article say?
ChartMill’s analysis rated Gilead Sciences (GILD) a 10/10 technical strength and an 8/10 breakout setup quality on October 2. The report highlighted entry, stop, and risk levels for traders. No fundamental or earnings data were discussed, and the assessment was purely technical in nature.
What did this article say?
Gilead Sciences shares rose 35% after Barron's spotlighted the company, reflecting investor enthusiasm. The article notes that key catalysts for the stock have yet to fully materialize, suggesting further upside potential. The performance underscores growing confidence in Gilead’s pipeline and market positioning.

Technical Analysis

Real-time indicators across multiple timeframes

45
NEUTRAL
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $75.49B combined position · 12 adding, 11 trimming, 2 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
BlackRock, Inc.▲ Buy121,844,1089.85%$15.39B2026-08-07
Vanguard Group Inc▲ Buy121,097,3369.79%$14.86B2026-01-29
FMR LLC (Fidelity)▼ Sell66,870,8165.41%$8.45B2026-08-13
Capital World Investors▼ Sell40,988,9753.31%$5.18B2026-08-12
Invesco Ltd.▲ Buy39,819,1513.22%$5.03B2026-08-14
Geode Capital Management, LLC▲ Buy30,065,6422.43%$3.80B2026-08-12
Morgan Stanley▲ Buy24,004,3541.94%$3.03B2026-08-13
Norges Bank▲ Buy21,965,5551.78%$2.78B2026-08-12
JPMorgan Chase & Co▼ Sell21,353,1211.73%$2.70B2026-08-12
Capital Research Global Investors▼ Sell19,393,2961.57%$2.45B2026-08-12
Bank of America Corp▼ Sell18,649,0651.51%$2.36B2026-08-14
Northern Trust Corp▲ Buy13,828,0101.12%$1.75B2026-08-13
Wellington Management Group LLP▼ Sell12,699,6831.03%$1.60B2026-08-14
Goldman Sachs Group Inc▼ Sell11,199,9940.91%$1.42B2026-08-14
Wells Fargo & Company▼ Sell6,456,5860.52%$815.73M2026-08-14
Citadel Advisors LLC• Hold5,576,0440.45%$704.48M2026-09-02
AllianceBernstein L.P.▼ Sell4,613,3830.37%$642.97M2026-08-14
Susquehanna International Group, LLP▼ Sell4,162,9010.34%$525.94M2026-08-14
Citigroup Inc▲ Buy3,188,8590.26%$402.88M2026-08-03
D. E. Shaw & Co., Inc.▲ Buy2,485,0890.20%$313.97M2026-08-14
Renaissance Technologies LLC▲ Buy2,217,3760.18%$280.14M2026-08-13
Millennium Management LLC▼ Sell2,179,8240.18%$275.40M2026-08-14
Janus Henderson Group plc• Hold1,972,6390.16%$274.92M2026-05-18
Squarepoint Ops LLC▲ Buy1,884,7240.15%$238.12M2026-08-14
Prudential Financial Inc▲ Buy1,759,3490.14%$222.28M2026-08-12
Q2 2026 flow:23.33M sh bought ($2.95B)31.05M sh sold ($3.94B)net -7.72M sh (−$989.35M)
Congressional Trading Activity
25 disclosed trades · ~$249.0K est. traded value · 15 buys, 10 sells
MemberChamberStateTypeAmountTradedFiled
Jared MoskowitzHouseFL23▲ Buy$1K - $15K2026-05-062026-06-19
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Josh GottheimerHouseNJ05▲ Buy$1K - $15K2026-01-272026-02-26
Valerie HoyleHouseOR04▼ Sell$1K - $15K2025-09-232025-10-10
Marjorie Taylor GreeneHouseGA14▲ Buy$1K - $15K2025-06-062025-06-18
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2025-05-142025-06-11
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-05-122025-06-22
Marjorie Taylor GreeneHouseGA14▲ Buy$1K - $15K2025-05-052025-05-06
John BoozmanSenateAR▼ Sell$1K - $15K2025-04-162025-05-14
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-03-312025-04-11
Carol Devine MillerHouseWV01▲ Buy$1K - $15K2025-03-102025-04-11
Josh GottheimerHouseNJ05▲ Buy$1K - $15K2025-03-072025-04-10
Valerie HoyleHouseOR04▲ Buy$1K - $15K2024-10-292025-09-12
Tommy TubervilleSenateAL▲ Buy$1K - $15K2024-05-102026-08-05
Tommy TubervilleSenateAL▼ Sell$1K - $15K2024-05-082026-08-05
Tommy TubervilleSenateAL▲ Buy$1K - $15K2024-04-052024-05-15
Tommy TubervilleSenateAL▼ Sell$1K - $15K2024-04-032024-05-15
Tommy TubervilleSenateAL▼ Sell$1K - $15K2022-01-132022-02-14
Jerry MoranSenate-▼ Sell$1K - $15K2021-12-212022-01-21
Jerry MoranSenate-▲ Buy$1K - $15K2020-08-212020-09-08
Jerry MoranSenate-▲ Buy$1K - $15K2019-09-252020-08-05
Shelley Moore CapitoSenateWV▼ Sell$1K - $15K2019-03-112019-04-17
Shelley Moore CapitoSenateWV▲ Buy$1K - $15K2018-09-252018-10-18
Angus KingSenate-▼ Sell$1K - $15K2018-04-232018-05-22
Shelley Moore CapitoSenateWV▲ Buy$1K - $15K2017-10-252017-11-07